CA3054823A1 - Forms and compositions of a mk2 inhibitor - Google Patents

Forms and compositions of a mk2 inhibitor Download PDF

Info

Publication number
CA3054823A1
CA3054823A1 CA3054823A CA3054823A CA3054823A1 CA 3054823 A1 CA3054823 A1 CA 3054823A1 CA 3054823 A CA3054823 A CA 3054823A CA 3054823 A CA3054823 A CA 3054823A CA 3054823 A1 CA3054823 A1 CA 3054823A1
Authority
CA
Canada
Prior art keywords
compound
acid
complex
peaks
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3054823A
Other languages
English (en)
French (fr)
Inventor
Jianxin HAN
Lianfeng Huang
Uday Jain
Ying Li
John MALONA
Kevin MOLTER
Chittari Pabba
Alexander L. Ruchelman
Jean Xu
Daozhong Zou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Celgene CAR LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene CAR LLC filed Critical Celgene CAR LLC
Publication of CA3054823A1 publication Critical patent/CA3054823A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
CA3054823A 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor Pending CA3054823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472015P 2017-03-16 2017-03-16
US62/472,015 2017-03-16
PCT/US2018/022543 WO2018170199A1 (en) 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor

Publications (1)

Publication Number Publication Date
CA3054823A1 true CA3054823A1 (en) 2018-09-20

Family

ID=63522534

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3054823A Pending CA3054823A1 (en) 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor

Country Status (8)

Country Link
US (2) US10882867B2 (https=)
EP (1) EP3595658A4 (https=)
JP (2) JP2020514360A (https=)
CN (1) CN110678178B (https=)
AU (1) AU2018236286B2 (https=)
CA (1) CA3054823A1 (https=)
MX (1) MX393600B (https=)
WO (1) WO2018170199A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2018170200A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511882A (ja) * 1996-04-12 2000-09-12 ブリストル―マイヤーズ・スクイブ・カンパニー Ａｃｅ阻害剤及び／またはｎｅｐ阻害剤として有用なｎ―ホルミルヒドロキシルアミン化合物
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
US7790712B2 (en) * 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶系统的调节方法
MX2009014247A (es) 2007-07-16 2010-01-28 Novartis Ag Compuestos heterociclicos utiles como inhibidores de mk2.
WO2011062765A2 (en) * 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
AU2012244549B2 (en) * 2011-04-21 2017-04-20 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2014210319A2 (en) * 2013-06-26 2014-12-31 The Trustees Of Columbia University In The City Of New York Inhibitors of plasmodium falciparum equilibrative nucleoside transporter type 1 as anti-parasitic compounds
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
RS62017B1 (sr) * 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
EP3242886A4 (en) 2015-01-08 2018-08-29 Moerae Matrix, Inc., Formulation of mk2 inhibitor peptides
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体

Also Published As

Publication number Publication date
WO2018170199A1 (en) 2018-09-20
EP3595658A4 (en) 2020-11-25
JP2023017840A (ja) 2023-02-07
CN110678178B (zh) 2023-10-03
AU2018236286B2 (en) 2022-02-17
AU2018236286A1 (en) 2019-09-19
MX393600B (es) 2025-03-24
US10882867B2 (en) 2021-01-05
CN110678178A (zh) 2020-01-10
MX2019010643A (es) 2019-10-17
US20210198276A1 (en) 2021-07-01
EP3595658A1 (en) 2020-01-22
US20200148701A1 (en) 2020-05-14
US11629153B2 (en) 2023-04-18
JP2020514360A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
US11629153B2 (en) Forms and compositions of a MK2 inhibitor
US20210188813A1 (en) Ezh2 inhibitor and pharmaceutically acceptable salts and polymorphic substances thereof, and application of ezh2 inhibitor
JP2023051962A (ja) ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用
AU2018236290A1 (en) MK2 inhibitors, synthesis thereof, and intermediates thereto
EP3307732A1 (en) Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
TW202337447A (zh) 含氮并環類衍生物抑制劑的酸式鹽或晶型及其製備方法和應用
HK1256825A1 (zh) 取代的5，6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物的固体形式
EP4134369B1 (en) Solid forms of tetrahydropyranyl amino-pyrrolopyrimidinone compounds
US10544137B2 (en) PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof
CA3041854C (en) PYRIDO DERIVATIVE CRYSTAL [3,4-D]PYRIMIDINE OR ITS SOLVA
JP2026508943A (ja) 結晶形態
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
KR20200100615A (ko) 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의 고체 형태
CN118251400A (zh) Axl激酶抑制剂的盐、其制备方法和用途
KR20160143842A (ko) 치환된 이미다조피리디닐-아미노피리딘 화합물의 염 및 다형체
WO2025217647A1 (en) Stat6 degraders and uses thereof
WO2025242167A1 (zh) Pkmyt1抑制剂的多晶型、其制备方法及其应用
WO2025236004A1 (en) Stat6 inhibitors and uses thereof
WO2025011618A9 (zh) 噻唑并吡嗪类化合物的盐或其结晶及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230207

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240903

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251110